Heron Therapeutics (NASDAQ:HRTX) hit a new 52-week high and low during mid-day trading on Thursday . The company traded as low as $33.95 and last traded at $33.60, with a volume of 38253 shares. The stock had previously closed at $32.25.
A number of equities research analysts have issued reports on the company. BidaskClub upgraded Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Cowen reiterated a “buy” rating and issued a $48.00 price target on shares of Heron Therapeutics in a research note on Tuesday, May 8th. Cantor Fitzgerald set a $40.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Sunday, April 22nd. Oppenheimer set a $34.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 10th. Finally, Lake Street Capital set a $42.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 5th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $36.54.
The stock has a market cap of $2.40 billion, a price-to-earnings ratio of 8.95 and a beta of 1.88.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.81) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.06. The firm had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.10 million. Heron Therapeutics had a negative return on equity of 239.94% and a negative net margin of 515.27%. The business’s revenue was up 222.2% on a year-over-year basis. research analysts predict that Heron Therapeutics will post -2.4 earnings per share for the current year.
In other news, Director Kevin C. Tang acquired 192,308 shares of the business’s stock in a transaction dated Thursday, March 29th. The stock was purchased at an average price of $26.00 per share, for a total transaction of $5,000,008.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Barry D. Quart sold 100,000 shares of the firm’s stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $29.75, for a total value of $2,975,000.00. Following the transaction, the chief executive officer now owns 167,993 shares of the company’s stock, valued at approximately $4,997,791.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 218,000 shares of company stock valued at $5,990,000. Company insiders own 19.93% of the company’s stock.
Several institutional investors have recently modified their holdings of HRTX. Quantbot Technologies LP bought a new position in shares of Heron Therapeutics in the 1st quarter valued at about $117,000. SG Americas Securities LLC bought a new position in shares of Heron Therapeutics in the 1st quarter valued at about $183,000. Ellington Management Group LLC bought a new position in shares of Heron Therapeutics in the 4th quarter valued at about $195,000. Pinnacle Associates Ltd. bought a new position in shares of Heron Therapeutics in the 4th quarter valued at about $201,000. Finally, Jefferies Group LLC bought a new position in shares of Heron Therapeutics in the 4th quarter valued at about $214,000. Hedge funds and other institutional investors own 96.35% of the company’s stock.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.